首页> 外文期刊>Japanese Journal of Ophthalmology >Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-Month results of a Korean RVO study
【24h】

Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-Month results of a Korean RVO study

机译:视网膜静脉阻塞继发性黄斑水肿的早期治疗可改善视觉效果:一项韩国RVO研究的6个月结果

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO). Methods: Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for <6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months. Results: One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (<2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease. Conclusions: Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.
机译:目的:确定韩国视网膜静脉阻塞(RVO)患者的黄斑水肿(ME)持续时间与视觉结果之间的相关性。方法:多中心介入病例系列。初治患者(n = 249)的分支或中央RVO(BRVO / CRVO)和ME <6个月。我们评估了ME持续时间与治疗结局之间的相关性,包括最小分辨角最佳对数视力(logMAR BCVA)改善的平均对数,BCVA至少获得3线增加的患者比例以及6个月时平均视网膜中央厚度(CRT)减少。结果:156例BRVO患者和93例CRVO患者根据ME的持续时间(<2、2-4周,1-2、2-3、3-6个月)分为五组;各组之间的平均基线BCVA和CRT没有显着差异。在BRVO中,两组的最小分辨角(logMAR)BCVA改善的平均对数分别为0.51、0.32、0.17、0.19和0.13(P = 0.002)。至少三线增益的百分比分别为64%,53%,39%,38%和21%(P <0.001)。 BCVA的CRVO没有明显改善。两种疾病中CRT的降低与ME的持续时间均无显着相关。结论:MEVO发生后2周就开始治疗BRVO可以增强视觉效果。 CRVO患者没有相关性。这一发现支持了目前的趋势,即倾向于早期治疗以使BRVO患者获得更好的视觉效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号